BiotechTube
Kaerus Bioscience

Kaerus Bioscience

Cambridge, United Kingdom· Est.
kaerusbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Kaerus Bioscience is a private, preclinical-stage biotech developing proprietary small molecule modulators of BK (KCa1.1) ion channels for rare neurodevelopmental disorders. Its lead program, KER-0193, targets the underlying neuronal hyperexcitability in Fragile X syndrome, with a parallel program for KCNMA1-linked channelopathies. The company is built on a specialized scientific platform and led by a team with deep drug development experience, aiming to address significant unmet needs in niche, genetically-defined patient populations.

Neurodevelopmental DisordersRare Genetic Diseases

Technology Platform

Proprietary platform for developing small molecule modulators of BK (KCa1.1) potassium channels to address neuronal hyperexcitability in genetic neurodevelopmental disorders.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The high unmet need in Fragile X syndrome and ultra-rare KCNMA1-channelopathies presents a clear market for a disease-modifying therapy, with potential for orphan drug incentives and premium pricing.
Success in initial indications could validate the BK channel platform for expansion into other neurological disorders characterized by neuronal hyperexcitability.

Risk Factors

The primary risks are high scientific/clinical risk associated with a novel mechanism, dependence on future financing rounds as a private company, and competition from other entities developing treatments for Fragile X syndrome.
The transition from preclinical to clinical stages carries significant execution risk.

Competitive Landscape

The competitive landscape for disease-modifying Fragile X treatments is emerging but not yet crowded, with several companies exploring different mechanisms (e.g., mGluR5 antagonists, GABA modulators). For KCNMA1-linked channelopathies, Kaerus appears to be a pioneer. The key differentiator is Kaerus's focused approach on BK channel modulation, a distinct pathway.

More companies in United Kingdom →